Logo

Shionogi to Acquire Tetra Therapeutics for ~$500M

Share this

M&A

Shionogi to Acquire Tetra Therapeutics for ~$500M

Shots:

  • Shionogi to acquire Tetra for a total value of up to $500M which includes regulatory and commercial milestones- based on certain achievements. Following the acquisition- Shionogi will get global rights to Tetra’s portfolio for CNS disorders including BPN14770
  • In 2018- the two companies collaborated and in 2020 expand their alliance to develop and commercialize BPN14770 for AD- FXS- and other indications. Additionally- Tetra is evaluating BPN14770 in a P-II study for FXS and has completed a P-II study for AD in the US
  • BPN14770 is a selective inhibitor of phosphodiesterase-4D- having a potential to improve cognitive and memory function in CNS disorders and has received the US FDA’s ODD for FXS

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: StraitTimes

Related News: Tetra Therapeutics and Shionogi Expand their Existing 2018 Collaboration to Develop and Commercialize BPN14770


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions